Product Details
| Product Name:
COH-SR4 |
CAS No.:
73439-19-7 |
| Purity:
98.96% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | COH-SR4 |
| Description | COH-SR4 (COH-SR4 (Mitochondria uncoupler SR4)) is a uncoupler of mitochondrial oxidative phosphorylation. COH-SR4 modulates amp-dependent kinase (ampk)-mammalian target of rapamycin (mtor) signaling, and inhibiting proliferation of hepg2 hepatocarcinoma cells |
| In vivo | SR4 is a novel mitochondrial uncoupler with anti-obesity and anti-diabetic properties.?SR4 increased oxygen consumption, dissipated mitochondrial membrane potential, induced mitochondrial swelling, and decreased intracellular ATP in cultured cells and isolated liver mitochondria.?Oral feeding of SR4 significantly reduced body weight gain, improved glycemic control and insulin resistance, and prevented dyslipidemia in both high-fat-diet (HFD) induced obese and diabetic db/db mice.?SR4 treatment also decreased liver triglycerides and prevented hepatic steatosis in both animal models.?Mitochondrial uncoupling of SR4 results to activation of AMP-activated protein kinase (AMPK), leading to the phosphorylation and inhibition of acetyl-CoA carboxylase (ACC).?Gene analyses by RT-PCR showed SR4 significantly suppressed the mRNA expression of several lipogenic genes and gluconeogenic genes in the liver of HFD obese mice.?RNA sequencing analysis showed that 642 genes were differentially expressed in liver of db/db mice after SR4 treatment (217 upregulated, 425 down-regulated).?Gene ontology analysis by DAVID indicated SR4 upregulated amino acid metabolism and down-regulated lipid and fatty acid synthesis and glucose metabolism.?These studies demonstrate that SR4 may be a promising compound for treatment of T2DM and obesity |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4 mg/mL (11.43 mM)
|
| Keywords | anticancer | anti-proliferative | kinase | leukemia | protein | breast | cancers | lung | COH SR4 | COH-SR4 | COHSR4 | anti-adipogenic | COH-SR-4 | Inhibitor | AMPK | melanoma | inhibit | AMP-activated protein kinase | Mitochondria uncoupler SR4 | AMP-activated |
| Inhibitors Related | Phenformin hydrochloride | AICAR | Doxorubicin hydrochloride | Adenosine monophosphate | Metformin | Methyl cinnamate | A-769662 | Metformin hydrochloride | Chitosan oligosaccharide | Buformin hydrochloride | HTH-01-015 | AMPK activator 4 |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Cancer Active Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:220088-42-6
$673.00 / 10mg
-
CAS:1462249-75-7
$30.00 / 1mg
-
CAS:823202-99-9
$31.00 / 50mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-23 |
United States